Sara Bleve

5PUBLICATIONS
48CO-AUTHORS
Cancer geneticsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 27, 2026
Reply to: Time-Varying Effects of Copy Number Alteration Clustering: Methodologic Concerns in Survival Analysis of Relapsed/Refractory Germ Cell Tumors.

|Apr 03, 2026
Suppression of de novo lipogenesis and dietary PUFA supplementation inhibit prostate cancer progression.

Silvia D Rodrigues, Caroline Fidalgo Ribeiro, Giuseppe N Fanelli

|Mar 13, 2026
Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy.

Sara Bleve, Francesco Ravera, Silvia Rodrigues

|Feb 19, 2026
Impact of Circulating Tumor DNA and Copy-Number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated With Salvage High-Dose Chemotherapy.

Milena Urbini, Thomas F Eleveld, Maurizio Polano

|Oct 13, 2025
Liquid Biopsy Identifies Taxane Resistance and Clonal Selection in Castration-Resistant Prostate Cancer.

Nicole Brighi, Daniel Wetterskog, Osvaldas Vainauskas

Pageof 1